Endocrine & Melanocortin · 10mg × 10 vials
Melanocortin receptor agonist (bremelanotide). MC4R-mediated central signaling; FDA-approved in another formulation for HSDD.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist and a close structural analogue of Melanotan II with the pigmentary activity largely removed. It is a non-selective agonist at MC1, MC3, MC4, and MC5 receptors, but the sexual-response effect is driven almost entirely by MC4R activation in the central nervous system, specifically the medial preoptic area of the hypothalamus and the paraventricular nucleus.
This is a fundamentally different mechanism from PDE5 inhibitors such as sildenafil, which act peripherally on penile blood flow. PT-141 acts centrally on desire and arousal signalling, increasing dopaminergic tone in pro-erectile pathways in male models and amplifying central sexual response in female subjects without requiring peripheral stimulation to initiate the cascade. Because the trigger is upstream of the vascular response, it has been studied in contexts where PDE5 inhibitors are ineffective, including psychogenic erectile dysfunction, low-desire states, and SSRI-associated sexual dysfunction. The FDA approved bremelanotide as Vyleesi in June 2019 for hypoactive sexual desire disorder in premenopausal women, its only approved indication.
What the published studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
](https://pubmed.ncbi.nlm.nih.gov/31135737/) - pivotal Phase 3 efficacy/safety in 1247 premenopausal women with HSDD
Read study ↗PubMedKingsberg et al, Bremelanotide for HSDD: Two Randomized Phase 3 Trials, Obstetrics & Gynecology 2019primary efficacy paper
Read study ↗PubMedMelanocortin receptor agonists and sexual function, IJIR 2008early male ED data, intranasal bremelanotide
Read study ↗PubMedPT-141 mechanism review, Pharmacol Rev 2018melanocortin pathway in central sexual response
Read study ↗PubMedBremelanotide BP and CV safety profile, J Sex Med 2019transient BP increases, CV monitoring guidance
Read study ↗Clinical guidelinesFDA Vyleesi approval announcement, June 2019official FDA approval for HSDD in premenopausal women
Read study ↗Storage: refrigerated, stable ~30-45 days reconstituted. Unmixed vials are stable at room temp short-term but refrigerate for long storage.